TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes

Introduction Chronic activation of self-reactive T cells with beta cell antigens results in the upregulation of immune checkpoint molecules that keep self-reactive T cells under control and delay beta cell destruction in autoimmune diabetes. Inhibiting PD1/PD-L1 signaling results in autoimmune diabetes in mice and humans with pre-existing autoimmunity against beta cells. However, it is not known if other immune checkpoint molecules, such as TIGIT, can also negatively regulate self-reactive T cells. TIGIT negatively regulates the CD226 costimulatory pathway, T-cell receptor (TCR) signaling, and hence T-cell function. Methods The phenotype and function of TIGIT expressing islet infiltrating T cells was studied in non-obese diabetic (NOD) mice using flow cytometry and single cell RNA sequencing. To determine if TIGIT restrains self-reactive T cells, we used a TIGIT blocking antibody alone or in combination with anti-PDL1 antibody. Results We show that TIGIT is highly expressed on activated islet infiltrating T cells in NOD mice. We identified a subset of stem-like memory CD8+ T cells expressing multiple immune checkpoints including TIGIT, PD1 and the transcription factor EOMES, which is linked to dysfunctional CD8+ T cells. A known ligand for TIGIT, CD155 was expressed on beta cells and islet infiltrating dendritic cells. However, despite TIGIT and its ligand being expressed, islet infiltrating PD1+TIGIT+CD8+ T cells were functional. Inhibiting TIGIT in NOD mice did not result in exacerbated autoimmune diabetes while inhibiting PD1-PDL1 resulted in rapid autoimmune diabetes, indicating that TIGIT does not restrain islet infiltrating T cells in autoimmune diabetes to the same degree as PD1. Partial inhibition of PD1-PDL1 in combination with TIGIT inhibition resulted in rapid diabetes in NOD mice. Discussion These results suggest that TIGIT and PD1 act in synergy as immune checkpoints when PD1 signaling is partially impaired. Beta cell specific stem-like memory T cells retain their functionality despite expressing multiple immune checkpoints and TIGIT is below PD1 in the hierarchy of immune checkpoints in autoimmune diabetes.

[1]  A. Kallies,et al.  Extraislet expression of islet antigen boosts T cell exhaustion to partially prevent autoimmune diabetes. , 2024, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Jonjić,et al.  TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation , 2023, Nature communications.

[3]  L. Piemonti,et al.  Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I−/− iPSCs for β cell replacement , 2022, Cell reports.

[4]  R. Germain,et al.  TGF-β regulates the stem-like state of PD-1+ TCF-1+ virus-specific CD8 T cells during chronic infection , 2022, The Journal of experimental medicine.

[5]  E. Wherry,et al.  Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3 , 2022, Nature Immunology.

[6]  Thomas D. Wu,et al.  Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses , 2022, Immunity.

[7]  L. Boon,et al.  Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor , 2022, Clinical & translational immunology.

[8]  Francisco J. Sánchez-Rivera,et al.  An autoimmune stem-like CD8 T cell population drives type 1 diabetes , 2021, Nature.

[9]  David M. Schauder,et al.  Self-Renewing Islet TCF1+ CD8 T Cells Undergo IL-27–Controlled Differentiation to Become TCF1− Terminal Effectors during the Progression of Type 1 Diabetes , 2021, The Journal of Immunology.

[10]  E. Unanue,et al.  Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice , 2020, Proceedings of the National Academy of Sciences.

[11]  A. Dejean,et al.  Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. , 2020, Immunity.

[12]  M. Atkinson,et al.  CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation , 2020, Frontiers in Immunology.

[13]  E. Choi,et al.  CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy , 2020, Cancer Immunology Research.

[14]  A. Oxenius,et al.  TIGIT limits immune pathology during viral infections , 2020, Nature Communications.

[15]  G. Freeman,et al.  Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection. , 2019, Immunity.

[16]  S. Berger,et al.  TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. , 2019, Immunity.

[17]  E. Wherry,et al.  Defining ‘T cell exhaustion’ , 2019, Nature Reviews Immunology.

[18]  M. Delorenzi,et al.  TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection , 2019, Nature.

[19]  Yong Liu,et al.  TOX is a critical regulator of tumour-specific T cell differentiation , 2019, Nature.

[20]  S. Berger,et al.  TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion , 2019, Nature.

[21]  F. Hodi,et al.  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.

[22]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[23]  C. D. De Block,et al.  Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus , 2018, The Journal of clinical endocrinology and metabolism.

[24]  Dai Fukumura,et al.  Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity , 2018, The Journal of Immunology.

[25]  A. Sharpe Introduction to checkpoint inhibitors and cancer immunotherapy , 2017, Immunological reviews.

[26]  A. Elkahloun,et al.  The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness , 2016, Science Immunology.

[27]  James A. Eddy,et al.  Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes , 2016, Science Immunology.

[28]  Sandra P. Calderon-Copete,et al.  T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. , 2016, Immunity.

[29]  Matheus C. Bürger,et al.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy , 2016, Nature.

[30]  G. Freeman,et al.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. , 2016, Immunity.

[31]  J. Hackney,et al.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.

[32]  A. Skowera,et al.  Effector-Memory T Cells Develop in Islets and Report Islet Pathology in Type 1 Diabetes , 2014, The Journal of Immunology.

[33]  Z. Qiu,et al.  CD226 Gly307Ser association with multiple autoimmune diseases: a meta-analysis. , 2013, Human immunology.

[34]  Burton E. Barnett,et al.  Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection , 2012, Science.

[35]  H. Thomas,et al.  Intra‐islet proliferation of cytotoxic T lymphocytes contributes to insulitis progression , 2012, European journal of immunology.

[36]  D. Hafler,et al.  The TIGIT/CD226 Axis Regulates Human T Cell Function , 2012, The Journal of Immunology.

[37]  E. Wherry T cell exhaustion , 2011, Nature Immunology.

[38]  Vijay K. Kuchroo,et al.  Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions , 2011, The Journal of Immunology.

[39]  P. Muranski,et al.  Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.

[40]  E. Wherry,et al.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.

[41]  Nikhil S. Joshi,et al.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. , 2007, Immunity.

[42]  T. Okazaki,et al.  PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.

[43]  T. Okazaki,et al.  Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Khoury,et al.  The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice , 2003, The Journal of experimental medicine.

[45]  廷冕 李,et al.  応用 (Application) について , 1981 .

[46]  V. Kuchroo,et al.  Tim-3, Lag-3, and TIGIT. , 2017, Current topics in microbiology and immunology.

[47]  Y. Kawakami,et al.  Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. , 2016, The Journal of investigative dermatology.

[48]  H. Clark,et al.  The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells , 2009, Nature Immunology.